SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2152Don't know if sales is still around . . . here's the clinical updatetuck-7/27/2006
2151their most important genomic asset is their 30,000 royalty-bearing agreements. bsoftware salesperson-6/27/2006
2150That's what I thought a few years and few dollars back.tom pope-6/27/2006
2149Doesn't INCY have a gene patent portfolio, so to speak? Is this (option valuhoyasaxa-6/27/2006
2148They should ask themselves whether this might be a better business plan... Messanigel bates-6/21/2006
2147Incy pipeline 6/06: 1) sheddase inhibitor - - incb7839; solid tumors; p 1 / 2; software salesperson-6/20/2006
2146<i>Once more unto the breach...</i> Incyte Begins Phase I Study of nigel bates-5/10/2006
2145I know it's sunk cost, but still... <i>we had an accumulated deficit nigel bates-4/4/2006
2144Yes (esp. the current market cap.), but it's nice to have something to fall nigel bates-4/4/2006
2143Hi nigel, I have been looking at Incy too. Sheddase inhibitors are early and thdr.praveen-4/4/2006
2142$300m cap. doesn't look hideously expensive (in November the market thought nigel bates-4/4/2006
2141This is a good article on hyperlipasemia in HIV patients: hivdent.org This unfBiomaven-4/3/2006
2140Incyte to Discontinue Development of DFC as a Treatment for HIV Monday April 3, nigel bates-4/3/2006
2139Interesting article with implications for TELK as well. pharmaweek.comlarrytioga-2/28/2006
2138Dr. Hans Black, Guest Monitor on Friday's Nightly Business Report, recommendD.Lu-2/27/2006
2137Incyte Announces 2005 Financial Results and Provides 2006 Guidance Thursday Febrnigel bates-2/16/2006
2136MLNM today - <i>As part of the Company's ongoing portfolio managemennigel bates-1/26/2006
2135Just parking... Published online before print February 24, 2005, doi:10.1161/01sim1-1/19/2006
2134New Study Shows That Elevated Lp-PLA2 Signals Early Endothelial Dysfunction, a Mnigel bates-1/18/2006
2133from h&q 3 or 4 new compounds in clinic in ’06: 1st ½ - - ccr5 for hsoftware salesperson-1/12/2006
2132[CCR2 modulates inflammatory and metabolic effects of high-fat feeding] >>tuck-1/9/2006
2131Here's the raw transcript of the CCR2 cc. - micro INCYTE CORP Conference Cmicrocapfun-1/2/2006
2130cc on pfe deal pfe will pay for and design trials no comment on level of royalsoftware salesperson-11/21/2005
2129I'm out. Will try to follow the program however.keokalani'nui-11/21/2005
2128Was considering buying some last week to lower my overall basis but never pulledFiloF-11/21/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News